A Phase II study of paclitaxel by 24-hour infusion and ifosfamide in anthracycline-resistant metastatic breast carcinoma

Jae Hong Seo, Young M. Whang, Byung Soo Kim, Chul Won Choi, Sang Won Shin, Yeul Hong Kim, Jun Suk Kim, Bum H. Goo

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

BACKGROUND. A Phase II study was performed to investigate the efficacy and tolerability of paclitaxel and ifosfamide chemotherapy for the treatment of anthracycline-resistant metastatic breast carcinoma (MBC). METHODS. Recurrent or progressed MBC within 12 months after anthracycline-based chemotherapy was defined as anthracycline-resistant. A 24-hour infusion of paclitaxel (175 mg/m2) on Day 1 and subsequent infusions of ifosfamide (1.8 g/m2/day) with mesna (360 mg/m2/day) on Days 2-4, were performed every 3 weeks. Twenty-one patients were eligible for toxicity analysis. Response rate and survival duration were evaluated in 21 patients. Frontline chemotherapy was the FAC (5-fluorouracil, doxorubicin, cyclophosphamide) regimen in all patients. RESULTS. Objective response was found in 9 patients (42.9%), including complete response in 3 (13.4%). Median response duration and median survival duration were 10 months (range, 2-24+) and 19+ months (range, 2-32+), respectively. Sixteen (76%) experienced Grade 3/4 leukopenia controllable with granulocyte macrophage colony-stimulating factor. Other significant toxicities were peripheral neuropathy (n = 3), mucositis (n = 2), and liver dysfunction (n = 1). However, there was no chemotherapy-related death. CONCLUSIONS. Paclitaxel by 24-hour infusion combined with ifosfamide is efficacious in the treatment of anthracycline-resistant MBC with tolerable toxicity. Further trials verifying the result of the authors' study are warranted.

Original languageEnglish
Pages (from-to)1925-1930
Number of pages6
JournalCancer
Volume94
Issue number7
DOIs
Publication statusPublished - 2002 Apr 1

Fingerprint

Ifosfamide
Anthracyclines
Paclitaxel
Breast Neoplasms
Drug Therapy
Mesna
Mucositis
Leukopenia
Peripheral Nervous System Diseases
Granulocyte-Macrophage Colony-Stimulating Factor
Fluorouracil
Doxorubicin
Cyclophosphamide
Liver Diseases
Survival Rate
Survival
Therapeutics

Keywords

  • Anthracycline resistance
  • Breast carcinoma
  • Ifosfamide
  • Paclitaxel

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

A Phase II study of paclitaxel by 24-hour infusion and ifosfamide in anthracycline-resistant metastatic breast carcinoma. / Seo, Jae Hong; Whang, Young M.; Kim, Byung Soo; Choi, Chul Won; Shin, Sang Won; Kim, Yeul Hong; Kim, Jun Suk; Goo, Bum H.

In: Cancer, Vol. 94, No. 7, 01.04.2002, p. 1925-1930.

Research output: Contribution to journalArticle

@article{488305209a1d4cf796e5434fe3b9ba90,
title = "A Phase II study of paclitaxel by 24-hour infusion and ifosfamide in anthracycline-resistant metastatic breast carcinoma",
abstract = "BACKGROUND. A Phase II study was performed to investigate the efficacy and tolerability of paclitaxel and ifosfamide chemotherapy for the treatment of anthracycline-resistant metastatic breast carcinoma (MBC). METHODS. Recurrent or progressed MBC within 12 months after anthracycline-based chemotherapy was defined as anthracycline-resistant. A 24-hour infusion of paclitaxel (175 mg/m2) on Day 1 and subsequent infusions of ifosfamide (1.8 g/m2/day) with mesna (360 mg/m2/day) on Days 2-4, were performed every 3 weeks. Twenty-one patients were eligible for toxicity analysis. Response rate and survival duration were evaluated in 21 patients. Frontline chemotherapy was the FAC (5-fluorouracil, doxorubicin, cyclophosphamide) regimen in all patients. RESULTS. Objective response was found in 9 patients (42.9{\%}), including complete response in 3 (13.4{\%}). Median response duration and median survival duration were 10 months (range, 2-24+) and 19+ months (range, 2-32+), respectively. Sixteen (76{\%}) experienced Grade 3/4 leukopenia controllable with granulocyte macrophage colony-stimulating factor. Other significant toxicities were peripheral neuropathy (n = 3), mucositis (n = 2), and liver dysfunction (n = 1). However, there was no chemotherapy-related death. CONCLUSIONS. Paclitaxel by 24-hour infusion combined with ifosfamide is efficacious in the treatment of anthracycline-resistant MBC with tolerable toxicity. Further trials verifying the result of the authors' study are warranted.",
keywords = "Anthracycline resistance, Breast carcinoma, Ifosfamide, Paclitaxel",
author = "Seo, {Jae Hong} and Whang, {Young M.} and Kim, {Byung Soo} and Choi, {Chul Won} and Shin, {Sang Won} and Kim, {Yeul Hong} and Kim, {Jun Suk} and Goo, {Bum H.}",
year = "2002",
month = "4",
day = "1",
doi = "10.1002/cncr.10431",
language = "English",
volume = "94",
pages = "1925--1930",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "7",

}

TY - JOUR

T1 - A Phase II study of paclitaxel by 24-hour infusion and ifosfamide in anthracycline-resistant metastatic breast carcinoma

AU - Seo, Jae Hong

AU - Whang, Young M.

AU - Kim, Byung Soo

AU - Choi, Chul Won

AU - Shin, Sang Won

AU - Kim, Yeul Hong

AU - Kim, Jun Suk

AU - Goo, Bum H.

PY - 2002/4/1

Y1 - 2002/4/1

N2 - BACKGROUND. A Phase II study was performed to investigate the efficacy and tolerability of paclitaxel and ifosfamide chemotherapy for the treatment of anthracycline-resistant metastatic breast carcinoma (MBC). METHODS. Recurrent or progressed MBC within 12 months after anthracycline-based chemotherapy was defined as anthracycline-resistant. A 24-hour infusion of paclitaxel (175 mg/m2) on Day 1 and subsequent infusions of ifosfamide (1.8 g/m2/day) with mesna (360 mg/m2/day) on Days 2-4, were performed every 3 weeks. Twenty-one patients were eligible for toxicity analysis. Response rate and survival duration were evaluated in 21 patients. Frontline chemotherapy was the FAC (5-fluorouracil, doxorubicin, cyclophosphamide) regimen in all patients. RESULTS. Objective response was found in 9 patients (42.9%), including complete response in 3 (13.4%). Median response duration and median survival duration were 10 months (range, 2-24+) and 19+ months (range, 2-32+), respectively. Sixteen (76%) experienced Grade 3/4 leukopenia controllable with granulocyte macrophage colony-stimulating factor. Other significant toxicities were peripheral neuropathy (n = 3), mucositis (n = 2), and liver dysfunction (n = 1). However, there was no chemotherapy-related death. CONCLUSIONS. Paclitaxel by 24-hour infusion combined with ifosfamide is efficacious in the treatment of anthracycline-resistant MBC with tolerable toxicity. Further trials verifying the result of the authors' study are warranted.

AB - BACKGROUND. A Phase II study was performed to investigate the efficacy and tolerability of paclitaxel and ifosfamide chemotherapy for the treatment of anthracycline-resistant metastatic breast carcinoma (MBC). METHODS. Recurrent or progressed MBC within 12 months after anthracycline-based chemotherapy was defined as anthracycline-resistant. A 24-hour infusion of paclitaxel (175 mg/m2) on Day 1 and subsequent infusions of ifosfamide (1.8 g/m2/day) with mesna (360 mg/m2/day) on Days 2-4, were performed every 3 weeks. Twenty-one patients were eligible for toxicity analysis. Response rate and survival duration were evaluated in 21 patients. Frontline chemotherapy was the FAC (5-fluorouracil, doxorubicin, cyclophosphamide) regimen in all patients. RESULTS. Objective response was found in 9 patients (42.9%), including complete response in 3 (13.4%). Median response duration and median survival duration were 10 months (range, 2-24+) and 19+ months (range, 2-32+), respectively. Sixteen (76%) experienced Grade 3/4 leukopenia controllable with granulocyte macrophage colony-stimulating factor. Other significant toxicities were peripheral neuropathy (n = 3), mucositis (n = 2), and liver dysfunction (n = 1). However, there was no chemotherapy-related death. CONCLUSIONS. Paclitaxel by 24-hour infusion combined with ifosfamide is efficacious in the treatment of anthracycline-resistant MBC with tolerable toxicity. Further trials verifying the result of the authors' study are warranted.

KW - Anthracycline resistance

KW - Breast carcinoma

KW - Ifosfamide

KW - Paclitaxel

UR - http://www.scopus.com/inward/record.url?scp=0036534343&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036534343&partnerID=8YFLogxK

U2 - 10.1002/cncr.10431

DO - 10.1002/cncr.10431

M3 - Article

C2 - 11932893

AN - SCOPUS:0036534343

VL - 94

SP - 1925

EP - 1930

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 7

ER -